MSLN and breast neoplasm: Rare or absent MSLN positivity was observed in different subtypes of breast tumors (0% in 50 phyllodes, 0.9% in 294 lobular, 5.3% in 27 tubular, 6.6% in 1391 invasive no special type, and 10.9% in 58 mucinous subtypes), renal cell (0% in 177 oncocytomas, 1.6% in 131 chromophobe, 6.6% in 858 clear cell, and 8.7% in 255 papillary subtypes), and thyroid carcinomas (0% to 1.4%), as well as soft tissue tumors (0.3%), and adenocarcinomas of the prostate (0%).